Other formats:
BibTeX
LaTeX
RIS
@article{1830786, author = {Bedanova, H. and Horvath, V. and Ondrasek, J. and Krejčí, Jan and Dobšák, Petr and Nemec, P.}, article_location = {BRATISLAVA}, article_number = {5}, doi = {http://dx.doi.org/10.4149/BLL_2021_051}, keywords = {biguanide; heart graft; malignancy; diabetes mellitus; survival}, language = {eng}, issn = {0006-9248}, journal = {Bratislava Medical Journal - Bratislavské lekárske listy}, title = {Metformin therapy and risk of cancer in patients after heart transplantation}, url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1}, volume = {122}, year = {2021} }
TY - JOUR ID - 1830786 AU - Bedanova, H. - Horvath, V. - Ondrasek, J. - Krejčí, Jan - Dobšák, Petr - Nemec, P. PY - 2021 TI - Metformin therapy and risk of cancer in patients after heart transplantation JF - Bratislava Medical Journal - Bratislavské lekárske listy VL - 122 IS - 5 SP - 305-309 EP - 305-309 PB - Univerzita Komenského SN - 00069248 KW - biguanide KW - heart graft KW - malignancy KW - diabetes mellitus KW - survival UR - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1 N2 - BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk ER -
BEDANOVA, H., V. HORVATH, J. ONDRASEK, Jan KREJČÍ, Petr DOBŠÁK and P. NEMEC. Metformin therapy and risk of cancer in patients after heart transplantation. \textit{Bratislava Medical Journal - Bratislavské lekárske listy}. BRATISLAVA: Univerzita Komenského, 2021, vol.~122, No~5, p.~305-309. ISSN~0006-9248. Available from: https://dx.doi.org/10.4149/BLL\_{}2021\_{}051.
|